Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published online Oct. 23 in The BMJ.
Min He, from Fudan University Shanghai Cancer and Key Laboratory of Breast Cancer, and colleagues conducted a randomized phase 3 trial in seven cancer centers in China involving female patients aged 18 to 70 years with early triple-negative breast cancer after definitive surgery. After risk stratification using a multigene signature, patients at high risk were randomly allocated to receive an intensive treatment regimen composed of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin, or standard treatment (arm A: 166 patients; arm B: 170 patients). Patients at low risk received the same standard treatment (arm C: 168 patients).
The researchers found three-year disease-free survival rates of 90.9 and 80.6 percent for patients in arms A and B, respectively, at a median follow-up of 45.1 months (hazard ratio, 0.51). The three-year recurrence-free survival rate was 92.6 and 83.2 percent in arms A and B, respectively (hazard ratio, 0.50). The three-year overall survival rate did not differ significantly for patients in arms A and B. Patients in arm C had significantly higher rates of disease-free survival, recurrence-free survival, and overall survival than those in arm B receiving the same chemotherapy regimen.
"Intensive regimens incorporating gemcitabine and cisplatin led to significantly improved disease-free survival compared with standard anthracycline/taxane-based therapy in a well-defined subgroup of patients with operable triple-negative breast cancer," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
Exercise, Rehab Services Can Be Integrated Into Breast Cancer Care
MONDAY, April 28, 2025 -- Exercise and rehabilitation services for patients with breast cancer through a clinical workflow algorithm called CORE (Comprehensive Oncology...
Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema
THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema (BCRL), according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.